Hoth Historical Financial Ratios

HOTH Stock  USD 0.83  0.01  1.22%   
Hoth Therapeutics is recently reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.53 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Hoth Therapeutics financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

About Hoth Financial Ratios Analysis

Hoth TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Hoth Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Hoth financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Hoth Therapeutics history.

Hoth Therapeutics Financial Ratios Chart

As of now, Hoth Therapeutics' EV To Free Cash Flow is increasing as compared to previous years. The Hoth Therapeutics' current Net Debt To EBITDA is estimated to increase to 57.00, while PTB Ratio is projected to decrease to 0.53.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Hoth Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Hoth Therapeutics sales, a figure that is much harder to manipulate than other Hoth Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.
Most ratios from Hoth Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Hoth Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.As of now, Hoth Therapeutics' EV To Free Cash Flow is increasing as compared to previous years. The Hoth Therapeutics' current Net Debt To EBITDA is estimated to increase to 57.00, while PTB Ratio is projected to decrease to 0.53.
 2023 2024 (projected)
PB Ratio0.560.53
Capex To Depreciation184.64175.4

Hoth Therapeutics fundamentals Correlations

-0.510.350.11-0.17-0.071.00.13-0.96-0.230.16-0.22-0.16-0.5-0.06-0.220.03-0.13-0.050.06-0.96-0.06-0.35-0.91-0.130.37
-0.51-0.18-0.81-0.17-0.45-0.51-0.830.35-0.14-0.76-0.140.690.990.5-0.140.450.53-0.460.390.360.50.60.330.53-0.23
0.35-0.180.15-0.480.630.350.1-0.22-0.84-0.13-0.83-0.21-0.22-0.7-0.83-0.66-0.730.65-0.68-0.22-0.7-0.79-0.43-0.730.99
0.11-0.810.15-0.030.760.111.00.130.160.930.16-0.52-0.84-0.750.16-0.74-0.740.76-0.660.12-0.75-0.710.18-0.740.23
-0.17-0.17-0.48-0.03-0.3-0.170.00.050.230.080.24-0.19-0.080.340.240.320.36-0.310.370.060.340.390.090.36-0.55
-0.07-0.450.630.76-0.3-0.070.710.33-0.380.51-0.38-0.28-0.49-0.99-0.38-1.0-0.981.0-0.940.31-0.99-0.910.21-0.980.66
1.0-0.510.350.11-0.17-0.070.13-0.96-0.230.16-0.22-0.16-0.5-0.06-0.220.03-0.13-0.050.06-0.96-0.06-0.35-0.91-0.130.37
0.13-0.830.11.00.00.710.130.110.210.950.2-0.52-0.85-0.710.2-0.7-0.70.71-0.620.1-0.71-0.680.17-0.70.18
-0.960.35-0.220.130.050.33-0.960.110.180.060.180.090.33-0.20.18-0.29-0.130.3-0.291.0-0.20.10.95-0.12-0.22
-0.23-0.14-0.840.160.23-0.38-0.230.210.180.391.0-0.1-0.150.441.00.410.46-0.390.50.180.440.50.380.46-0.76
0.16-0.76-0.130.930.080.510.160.950.060.390.38-0.43-0.77-0.490.38-0.49-0.490.5-0.380.04-0.49-0.480.2-0.49-0.06
-0.22-0.14-0.830.160.24-0.38-0.220.20.181.00.38-0.1-0.150.431.00.410.45-0.390.50.180.430.490.380.46-0.75
-0.160.69-0.21-0.52-0.19-0.28-0.16-0.520.09-0.1-0.43-0.10.70.31-0.10.290.32-0.30.30.090.310.350.140.32-0.26
-0.50.99-0.22-0.84-0.08-0.49-0.5-0.850.33-0.15-0.77-0.150.70.54-0.150.490.57-0.510.430.340.540.640.310.57-0.29
-0.060.5-0.7-0.750.34-0.99-0.06-0.71-0.20.44-0.490.430.310.540.431.01.0-0.990.94-0.191.00.95-0.081.0-0.73
-0.22-0.14-0.830.160.24-0.38-0.220.20.181.00.381.0-0.1-0.150.430.410.45-0.390.50.180.430.490.380.46-0.75
0.030.45-0.66-0.740.32-1.00.03-0.7-0.290.41-0.490.410.290.491.00.410.99-1.00.95-0.280.990.92-0.170.98-0.69
-0.130.53-0.73-0.740.36-0.98-0.13-0.7-0.130.46-0.490.450.320.571.00.450.99-0.980.94-0.121.00.97-0.011.0-0.76
-0.05-0.460.650.76-0.311.0-0.050.710.3-0.390.5-0.39-0.3-0.51-0.99-0.39-1.0-0.98-0.950.29-0.99-0.920.18-0.980.68
0.060.39-0.68-0.660.37-0.940.06-0.62-0.290.5-0.380.50.30.430.940.50.950.94-0.95-0.280.940.87-0.130.93-0.7
-0.960.36-0.220.120.060.31-0.960.11.00.180.040.180.090.34-0.190.18-0.28-0.120.29-0.28-0.180.110.95-0.11-0.22
-0.060.5-0.7-0.750.34-0.99-0.06-0.71-0.20.44-0.490.430.310.541.00.430.991.0-0.990.94-0.180.96-0.071.0-0.73
-0.350.6-0.79-0.710.39-0.91-0.35-0.680.10.5-0.480.490.350.640.950.490.920.97-0.920.870.110.960.210.97-0.82
-0.910.33-0.430.180.090.21-0.910.170.950.380.20.380.140.31-0.080.38-0.17-0.010.18-0.130.95-0.070.210.0-0.41
-0.130.53-0.73-0.740.36-0.98-0.13-0.7-0.120.46-0.490.460.320.571.00.460.981.0-0.980.93-0.111.00.970.0-0.77
0.37-0.230.990.23-0.550.660.370.18-0.22-0.76-0.06-0.75-0.26-0.29-0.73-0.75-0.69-0.760.68-0.7-0.22-0.73-0.82-0.41-0.77
Click cells to compare fundamentals

Hoth Therapeutics Account Relationship Matchups

Hoth Therapeutics fundamentals Accounts

201920202021202220232024 (projected)
Ptb Ratio23.686.311.491.820.560.53
Book Value Per Share6.549.3911.064.282.594.27
Free Cash Flow Yield(0.0889)(0.22)(0.83)(1.0)(1.72)(1.63)
Operating Cash Flow Per Share(13.5)(12.4)(13.54)(7.76)(2.48)(2.6)
Pb Ratio23.686.311.491.820.560.53
Free Cash Flow Per Share(13.75)(12.74)(13.67)(7.83)(2.48)(2.6)
Roic(3.22)(1.53)(1.43)(2.22)(0.87)(0.91)
Net Income Per Share(20.99)(14.56)(16.03)(9.75)(2.3)(2.42)
Cash Per Share6.89.4911.685.542.734.59
Pocfratio(11.47)(4.78)(1.22)(1.0)(0.58)(0.61)
Pfcf Ratio(11.25)(4.65)(1.21)(1.0)(0.58)(0.61)
Days Payables Outstanding4.7K1.8K2.813.8K4.4K4.1K
Income Quality0.840.640.850.821.080.61
Roe(3.21)(1.55)(1.45)(2.28)(0.89)(0.93)
Ev To Operating Cash Flow(11.13)(4.35)(0.51)(0.31)0.510.54
Pe Ratio(7.37)(4.07)(1.03)(0.8)(0.63)(0.66)
Return On Tangible Assets(2.71)(1.37)(1.3)(1.73)(0.82)(0.87)
Ev To Free Cash Flow(10.92)(4.23)(0.51)(0.31)0.510.54
Earnings Yield(0.14)(0.25)(0.97)(1.25)(1.6)(1.52)
Net Debt To E B I T D A0.110.220.3660.3254.2857.0
Current Ratio5.9915.3212.194.8513.8912.34
Tangible Book Value Per Share6.549.3911.064.282.594.27
Graham Number55.5655.4763.1630.6311.5710.99
Shareholders Equity Per Share6.549.3911.064.282.594.27
Graham Net Net5.68.28(42.07)4.182.522.64
Enterprise Value Over E B I T D A(7.14)(3.65)(0.44)28.2625.4326.71
Price Earnings Ratio(7.37)(4.07)(1.03)(0.8)(0.63)(0.66)
Price Book Value Ratio23.686.311.491.820.560.53
Price Earnings To Growth Ratio(0.034)0.13(0.1)0.02040.0081890.008599
Days Of Payables Outstanding4.7K1.8K2.813.8K4.4K4.1K
Price To Operating Cash Flows Ratio(11.47)(4.78)(1.22)(1.0)(0.58)(0.61)
Price To Free Cash Flows Ratio(11.25)(4.65)(1.21)(1.0)(0.58)(0.61)
Effective Tax Rate0.0013450.02850.0(0.0269)(0.0309)(0.0293)
Company Equity Multiplier1.181.131.111.321.081.6

Currently Active Assets on Macroaxis

When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Return On Assets
(0.46)
Return On Equity
(0.83)
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.